BYSI Stock Overview
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.39|
|52 Week High||US$33.00|
|52 Week Low||US$1.13|
|1 Month Change||23.01%|
|3 Month Change||-37.39%|
|1 Year Change||-87.02%|
|3 Year Change||-94.14%|
|5 Year Change||-96.76%|
|Change since IPO||-91.73%|
Recent News & Updates
|BYSI||US Biotechs||US Market|
Return vs Industry: BYSI underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: BYSI underperformed the US Market which returned -18.5% over the past year.
|BYSI Average Weekly Movement||17.1%|
|Biotechs Industry Average Movement||13.0%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: BYSI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: BYSI's weekly volatility has decreased from 30% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.
BeyondSpring Fundamentals Summary
|BYSI fundamental statistics|
Is BYSI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BYSI income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.65|
|Net Profit Margin||-4,750.48%|
How did BYSI perform over the long term?See historical performance and comparison
Is BYSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BYSI?
Other financial metrics that can be useful for relative valuation.
|What is BYSI's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BYSI's PS Ratio compare to its peers?
|BYSI PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: BYSI is expensive based on its Price-To-Sales Ratio (40.1x) compared to the peer average (19.4x).
Price to Earnings Ratio vs Industry
How does BYSI's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: BYSI is expensive based on its Price-To-Sales Ratio (40.1x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is BYSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||40.1x|
|Fair PS Ratio||129.6x|
Price-To-Sales vs Fair Ratio: BYSI is good value based on its Price-To-Sales Ratio (40.1x) compared to the estimated Fair Price-To-Sales Ratio (129.6x).
Share Price vs Fair Value
What is the Fair Price of BYSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BYSI's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is BeyondSpring forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BYSI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BYSI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BYSI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BYSI's revenue (52.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: BYSI's revenue (52.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BYSI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has BeyondSpring performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BYSI is currently unprofitable.
Growing Profit Margin: BYSI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BYSI is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: BYSI has a negative Return on Equity (-258.59%), as it is currently unprofitable.
Discover strong past performing companies
How is BeyondSpring's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BYSI's short term assets ($75.1M) exceed its short term liabilities ($15.2M).
Long Term Liabilities: BYSI's short term assets ($75.1M) exceed its long term liabilities ($40.1M).
Debt to Equity History and Analysis
Debt Level: BYSI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if BYSI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BYSI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BYSI has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 23.5% each year.
Discover healthy companies
What is BeyondSpring current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BYSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BYSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BYSI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BYSI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BYSI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lan Huang (50 yo)
Dr. Lan Huang, Ph D., co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and serves as its Chairman and Chief Executive Officer. Dr. Huang Co-founded BeyondSpring Inc. and has been its Chairman and Chi...
Experienced Management: BYSI's management team is considered experienced (2.6 years average tenure).
Experienced Board: BYSI's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BeyondSpring Inc.'s employee growth, exchange listings and data sources
- Name: BeyondSpring Inc.
- Ticker: BYSI
- Exchange: NasdaqCM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$54.109m
- Shares outstanding: 38.93m
- Website: https://www.beyondspringpharma.com
Number of Employees
- BeyondSpring Inc.
- 28 Liberty Street
- 39th Floor
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/25 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.